METHOD OF DIFFERENTIAL DIAGNOSIS OF PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA Russian patent published in 2018 - IPC G01N33/574 G01N33/68 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology and molecular biology, and can be used for the differential diagnosis of prostate cancer (PCa) and benign prostatic hyperplasia (BPH). Method includes: obtaining sample of peripheral blood of the patient; the release of plasma from the sample; isolation of RNA from blood plasma; measurement of the level of expression of the hsa-miR-6085 microRNA, hsa-miR-6511b-5p, hsa-mir-6886, followed by the determination of the probability value (F) characterizing the risk of PCa, using the following formula: F = 0.87 × (L1 – 2.764) / 0.705 – 1.387 × (L2 – 3.918) / 0.868 + 1.501 × (L3 – 1.492) / 0.599 – 0.407, where L1, L2 and L3 – expression levels of hsa-miR-6085, hsa-miR-6511b-5p, hsa-mir-6886 microRNA, respectively. When the value F > 0 is obtained, the PC is diagnosed, upon receipt of F ≤ 0 – BPH.

EFFECT: invention allows to effectively diagnose prostate cancer and differential diagnosis of prostate cancer with benign prostatic hyperplasia, that allows to start timely and adequate therapy.

7 cl, 7 ex, 1 dwg, 5 tbl